These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 23894038)

  • 61. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
    Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial.
    Welt A; Marschner N; Lerchenmueller C; Decker T; Steffens CC; Koehler A; Depenbusch R; Busies S; Hegewisch-Becker S
    Breast Cancer Res Treat; 2016 Feb; 156(1):97-107. PubMed ID: 26927446
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Advocacy for a New Oncology Research Paradigm: The Model of Bevacizumab in Triple-Negative Breast Cancer in a French Cohort Study.
    Mery B; Rowinski E; Vallard A; Jacquin JP; Simoens X; Magné N; Doucey P
    Oncology; 2019; 97(1):1-6. PubMed ID: 30939479
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The role of angiogenesis inhibition in the treatment of breast cancer.
    Sledge GW; Rugo HS; Burstein HJ
    Clin Adv Hematol Oncol; 2006 Oct; 4(10 Suppl 21):1-10; quiz 11-2. PubMed ID: 17139244
    [TBL] [Abstract][Full Text] [Related]  

  • 65. First-line bevacizumab-paclitaxel in 220 patients with metastatic breast cancer: results from the AVAREG study.
    Dank M; Budi L; Piko B; Mangel L; Erfan J; Cseh J; Ruzsa A; Landherr L
    Anticancer Res; 2014 Mar; 34(3):1275-80. PubMed ID: 24596372
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.
    Pentheroudakis G; Kotoula V; Kouvatseas G; Charalambous E; Dionysopoulos D; Zagouri F; Koutras A; Papazisis K; Pectasides D; Samantas E; Dimopoulos MA; Papandreou CN; Fountzilas G
    Clin Breast Cancer; 2014 Oct; 14(5):330-8. PubMed ID: 24703319
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.
    Valachis A; Polyzos NP; Patsopoulos NA; Georgoulias V; Mavroudis D; Mauri D
    Breast Cancer Res Treat; 2010 Jul; 122(1):1-7. PubMed ID: 20063120
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.
    Obermannová R; Van Cutsem E; Yoshino T; Bodoky G; Prausová J; Garcia-Carbonero R; Ciuleanu T; Garcia Alfonso P; Portnoy D; Cohn A; Yamazaki K; Clingan P; Lonardi S; Kim TW; Yang L; Nasroulah F; Tabernero J
    Ann Oncol; 2016 Nov; 27(11):2082-2090. PubMed ID: 27573561
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Patients with metastatic breast cancer using bevacizumab as a treatment: is there still a role for it?
    Lohmann AE; Chia S
    Curr Treat Options Oncol; 2012 Jun; 13(2):249-62. PubMed ID: 22350496
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Clinical value of trastuzumab in the treatment of lapatinib-resistant HER2-positive metastatic breast cancer].
    Ma F; Xu BH; Li HH; Li Q; Zhang P; Yuan P; Wang JY; Fan Y; Li Q
    Zhonghua Zhong Liu Za Zhi; 2013 Jul; 35(7):521-4. PubMed ID: 24257305
    [TBL] [Abstract][Full Text] [Related]  

  • 71. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
    Cremolini C; Loupakis F; Masi G; Lonardi S; Granetto C; Mancini ML; Chiara S; Moretto R; Rossini D; Vitello S; Allegrini G; Tonini G; Bergamo F; Tomasello G; Ronzoni M; Buonadonna A; Bustreo S; Barbara C; Boni L; Falcone A
    Ann Oncol; 2016 May; 27(5):843-9. PubMed ID: 26861604
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
    Tappenden P; Jones R; Paisley S; Carroll C
    Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
    Miles DW; Chan A; Dirix LY; Cortés J; Pivot X; Tomczak P; Delozier T; Sohn JH; Provencher L; Puglisi F; Harbeck N; Steger GG; Schneeweiss A; Wardley AM; Chlistalla A; Romieu G
    J Clin Oncol; 2010 Jul; 28(20):3239-47. PubMed ID: 20498403
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.
    Yoshimoto M; Takao S; Hirata M; Okamoto Y; Yamashita S; Kawaguchi Y; Takami M; Furusawa H; Morita S; Abe C; Sakamoto J
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):331-8. PubMed ID: 22526409
    [TBL] [Abstract][Full Text] [Related]  

  • 75. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
    Rochlitz C; Bigler M; von Moos R; Bernhard J; Matter-Walstra K; Wicki A; Zaman K; Anchisi S; Küng M; Na KJ; Bärtschi D; Borner M; Rordorf T; Rauch D; Müller A; Ruhstaller T; Vetter M; Trojan A; Hasler-Strub U; Cathomas R; Winterhalder R;
    BMC Cancer; 2016 Oct; 16(1):780. PubMed ID: 27724870
    [TBL] [Abstract][Full Text] [Related]  

  • 76. First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from >2000 patients treated in the multicentre AVANTI study.
    Müller V; Ruhnke M; Hoffmann O; Grafe A; Tomé O; Fett W; Bruch HR; Sommer-Joos AK; Schneeweiss A
    Breast; 2021 Dec; 60():70-77. PubMed ID: 34488065
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies.
    Yamamoto Y; Yamashiro H; Schneeweiss A; Müller V; Gluz O; Klare P; Aktas B; Magdolna D; Büdi L; Pikó B; Mangel L; Toi M; Morita S; Ohno S
    Breast Cancer; 2023 Jan; 30(1):88-100. PubMed ID: 36057014
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Bevacizumab and breast cancer: current therapeutic progress and future perspectives.
    Yang SX
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1715-25. PubMed ID: 19954282
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review.
    Puglisi F; Rea D; Kroes MA; Pronzato P
    Cancer Treat Rev; 2016 Feb; 43():36-49. PubMed ID: 26827691
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients.
    Chen IC; Hu FC; Lin CH; Huang SM; Chang DY; Cheng AL; Lu YS
    Breast; 2021 Oct; 59():211-220. PubMed ID: 34298300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.